First-in-Human trial launches for promising new prostate cancer pill
NCT ID NCT06705686
Summary
This is the first study in people to test the safety of a new oral drug called (R)-9bMS for advanced prostate cancer that has spread and stopped responding to standard hormone therapies. The main goal is to find a safe dose and see how well patients tolerate the medication. About 40 men with this advanced stage of cancer will take the pill twice daily to help researchers understand its effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin Carbone Cancer Center (UWCCC) - Cancer Connect
Madison, Wisconsin, 53792, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.